0
Détail d'une collection
|
Documents disponibles dans la collection


Titre : Combination treatment with varenicline and nicotine replacement therapy Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Michael V. Burke, Auteur ; Richard D. Hurt, Auteur Editeur : Oxford University Press Année de publication : 2009 Collection : Nicotine and Tobacco Research num. Vol 11, n. 5 Importance : p. 572-576 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract
INTRODUCTION:
A paucity of data exists regarding the safety and effectiveness of combination treatment with varenicline and nicotine replacement therapy (NRT).
METHODS:
We reviewed the clinical experience of two groups of cigarette smokers enrolled in a residential tobacco treatment program: (a) patients receiving combination treatment with varenicline and NRT (N = 104) and (b) usual-care patients receiving treatment before the release of varenicline (N = 135).
RESULTS:
Demographic characteristics were similar between the two groups. Among smokers receiving varenicline and NRT, 71% used the nicotine patch with a mean dose of 32 mg/day (SD = 14) and 73% used at least two types of NRT. Adverse events were experienced by 39% (95% CI = 31%-49%) of patients receiving varenicline and NRT and by 59% (95% CI = 51%-67%) of usual-care patients during the residential program. A total of five patients (5%) discontinued varenicline due to adverse events, compared with one patient in the usual-care group. We did not observe a significant difference in the 30-day point prevalence smoking abstinence rate at 6 months between patients treated with varenicline and NRT (54%; 95% CI = 44%-64%) and usual-care patients (59%; 95% CI = 50%-66%).
DISCUSSION:
Our findings suggest that combination therapy with varenicline and NRT is safe and well tolerated among patients in a residential tobacco treatment program.Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7950 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005491 TA 6.2.3.1.4 EBB C Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effects of cigarette smoking cessation on breastfeeding duration Type de document : document électronique Auteurs : Tara, M. Higgins, Auteur ; Stephen, T. Higgins, Auteur ; Sarah, H. Heil, Auteur Editeur : Oxford University Press Année de publication : 2010 Collection : Nicotine and Tobacco Research num. 12:5 Importance : p. 483–488 Langues : Anglais (eng) Catégories : [DIVERS] personne:par sexe:femme:femme enceinte
[TABAC] étude
[TABAC] prévention:santé:promotion de la santé:alimentation:allaitement
[TABAC] sevrage tabagiqueIndex. décimale : TA 3.2.2.7 Grossesse et fœtus Résumé : Introduction:
The purpose of this study was to use data from controlled trials to examine whether smoking cessation increases breastfeeding duration. Correlational studies have confirmedassociations between smoking status and breastfeeding duration, but whether smoking cessation increases breastfeeding duration has not been established.
Methods:
Participants ( N = 158) were smokers at the start of prenatal care who participated in controlled trials on smoking cessation. Women were assigned to either an incentive-based intervention wherein they earned vouchers exchangeable for retail items by abstaining from smoking or a control condition where they received comparable vouchers independent of smoking status. Treatments were provided antepartum through 12-week postpartum. Maternal reports of breastfeeding collected at 2-,
4-, 8-, 12-, and 24-week postpartum were compared between treatment conditions. Whether women were exclusively breastfeeding was not investigated.
Results:
The incentive-based treatment signifi cantly increased breastfeeding duration compared with rates observed among women receiving the control treatment, with signifi cant differences between treatment conditions observed at 8-week (41% vs. 26%; odds ratio [ OR ] = 2.7, 95% CI = 1.3– 5.6, p = .01) and 12-week
(35% vs. 17%; OR = 3.4, 95% CI = 1.5– 7.6, p = .002) postpartum. No significant treatment effects on breastfeeding were observed at other assessments. Changes in smoking status mediated the effects of treatment condition on breastfeeding duration.
Conclusions:
These results provide evidence from controlled studies that smoking cessation increases breastfeeding duration, which, to our knowledge, has not been previously reportedEn ligne : https://doi.org/10.1093%2Fntr%2Fntq031 Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9576 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Efficacy of over-the-counter nicotine patch Type de document : texte imprimé Auteurs : Saul Shiffman, Auteur ; Jane Gorsline, Auteur ; W. Gorodetzky, Auteur Editeur : Oxford University Press Année de publication : 2002 Collection : Nicotine and Tobacco Research num. 4 Importance : p.477-483 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotineIndex. décimale : TA 6.2.3.1.2 Transcutané Résumé : Efficacité du patch à la nicotine en délivrance libre Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2864 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001579 TA 6.2.3.1.2 SHI E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus / Mohamadi Sarkar (2010)
Titre : Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus Type de document : texte imprimé Auteurs : Mohamadi Sarkar, Auteur ; Jianmin Liu, Auteur ; Tamara Koval, Auteur Editeur : Oxford University Press Année de publication : 2010 Collection : Nicotine and Tobacco Research num. Vol. 12 Importance : p. 105-116 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac non fumé:tabac à sucer:snus
[TABAC] étude
[TABAC] tabagisme:évaluation du tabagisme:marqueurIndex. décimale : TA 6.2.3.2 Autres produits Résumé : NTRODUCTION:
It has been reported that adult smokers (AS) may be considering smokeless tobacco products as an alternative to smoking. The objective of this study was to evaluate the change in exposure in AS using Marlboro snus (MSNUS) (a tobacco pouch product in test market in June 2007).
METHODS:
AS were randomized into the following groups--CS: subjects (n = 30) continue smoking their own brand; DU: subjects (n = 60) reduced their daily cigarette consumption by >or=50% and were allowed to use MSNUS; SN: subjects (n = 15) stopped smoking their cigarettes but were allowed to use MSNUS; NT: subjects (n = 15) were not allowed to use any tobacco products for the entire duration of the 8-day study. Biomarkers of smoke exposure (BOE) measured at baseline and postbaseline were 24-hr urinary excretion of metabolites of N-nitrosamines, nicotine (urine and plasma), aromatic amines, benzene, and polycyclic aromatic hydrocarbon; urine mutagenicity; and carboxyhemoglobin at various timepoints.
RESULTS:
Statistically significant (p DISCUSSION:
The proportionate reduction in exposure when reducing the number of cigarettes by 50% and using MSNUS, under the consumption patterns observed, suggest that the AS did not appear to alter their smoking behavior. The added exposure from MSNUS usage in this group was minimal. The AS sustained substantial reductions in exposure when using MSNUS exclusively.Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7957 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005499 TA 6.2.3.2 SAR E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Message framing for smoking cessation : the interaction of risk perceptions and gendrer Type de document : document électronique Auteurs : Benjamin, A. Toll, Auteur ; Peter Salovey, Auteur ; Stéphanie O'Malley, Auteur Editeur : Oxford University Press Année de publication : 2008 Collection : Nicotine and Tobacco Research num. 0:1 Importance : p. 195-200 Présentation : tab.,graph. Langues : Anglais (eng) Catégories : [DIVERS] personne:par sexe:femme
[DIVERS] personne:par sexe:homme
[TABAC] sevrage tabagique
[TABAC] tabagisme:risque:perception du risqueIndex. décimale : TA 6.2.1 Simples conseils, avis Résumé : Because quitting smoking is clearly linked to preventing health problems such as lung cancer, research on health message framing based on prospect theory suggests that gain-framed messages (i.e., emphasizing the benefits of quitting smoking) would be more persuasive in promoting cessation than loss-framed messages (i.e., emphasizing the costs of continuing to smoke). However, because women tend to anticipate greater perceived risk from quitting smoking than men, this may affect how receptive they are to specific message framing interventions. Data from 249 participants (129 females, 120 males) in a clinical trial of message framing for smoking cessation with bupropion were used to examine how gender differences in perceptions of the risks associated with quitting influence the effects of framed interventions using number of days to smoking relapse as the criterion. Perceived risk of quitting scores were dichotomized using a median split for the entire sample. Women reported a higher perceived risk of cessation than men. Participants who anticipated high risks associated with quitting smoking reported fewer days to relapse. Further, females in the gain-framed condition who reported low perceived risks of cessation had a greater number of days to relapse, as opposed to females in the loss-framed condition. These findings suggest that message framing interventions for smoking cessation should consider the influence of gender and risk perceptions associated with quitting on the effectiveness of framed interventions. Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9554 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
The efficacy of moderate-intensity exercise as an aid for smoking cessation in women / Bess H. Marcus (2005)
Titre : The efficacy of moderate-intensity exercise as an aid for smoking cessation in women : a randomized controlled trial. Type de document : texte imprimé Auteurs : Bess H. Marcus, Auteur ; Beth A. Lewis, Auteur ; Joseph Hogan, Auteur Editeur : Oxford University Press Année de publication : 2005 Collection : Nicotine and Tobacco Research num. 7 (6) Importance : p.871-880 Langues : Anglais (eng) Catégories : [DIVERS] personne:par sexe:femme
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:aide au sevrage
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] tabagisme:risque:facteur associé:sportIndex. décimale : TA 6.7 Facteurs influents (grossesse, adolescence…) Résumé : Efficacité de l'effort d'intensité modérée comme aide au sevrage tabagique chez les femmes Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2863 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002124 TA 6.7 MAR E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : The use of snus for quitting smoking compared with medical products Type de document : texte imprimé Auteurs : Karl Erik Lund, Auteur ; A. Mc Neill, Auteur ; Janne Scheffels, Auteur Editeur : Oxford University Press Année de publication : 2010 Collection : Nicotine and Tobacco Research Importance : 6 p. Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe du Nord:Norvège
[TABAC] chimie du tabac:tabac non fumé:tabac à sucer:snus
[TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : ntroduction: Given there are few experimental studies comparing the effects of snus and medicinal products for quitting smoking, self-reports from smokers who have used different methods for quitting smoking can be informative.
Methods: Fourteen thousand seven hundred and forty-four Norwegian men aged between 20 and 50 years were selected at random from a national representative web panel and sent a questionnaire by E-mail. Of the 7,170 (48.6%) who responded, there were 1,775 former and 1,808 current smokers. They were asked about the method they used and the outcome of their last attempt to quit smoking.
Results: In a regression model in which education, number of previous attempts to quit smoking, perception of risk, and age were controlled for, the odds ratio (OR) for reporting total abstinence at the time of the survey was significantly higher for those who had used varenicline (OR = 4.95, p
Discussion: Compared with medicinal nicotine products, snus and varenicline increased the probability of quitting smoking completely, but snus seemed to maintain nicotine dependence.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910876/ Format de la ressource électronique : HTML. PDF Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7961 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005502 TA 6.2.3 LUN U Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Varenicline and bupropion sustained-release combination therapy for smoking cessation / Jon O. Ebbert (2009)
Titre : Varenicline and bupropion sustained-release combination therapy for smoking cessation Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Ivana T. Croghan, Auteur ; Amit Sood, Auteur Editeur : Oxford University Press Année de publication : 2009 Collection : Nicotine and Tobacco Research num. Vol 11, n.3 Importance : p. 234-239 Présentation : tad., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract
INTRODUCTION:
Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy.
METHODS:
We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled.
RESULTS:
Seven-day point-prevalent smoking abstinence rates were 71% (95% CI = 54%-85%) at 3 months and 58% (95% CI = 41%-74%) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74% of subjects took at least 90% of the prescribed doses. The most common side effects were sleep disturbance (26%) and nausea (24%). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation.
DISCUSSION:
Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7947 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005488 TA 6.2.3.1.4 EBB V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Walking reduces cue-elicited cigarette cravings and withdrawal symptoms, and delays ad libitum smoking / Adrian Taylor (2007)
Titre : Walking reduces cue-elicited cigarette cravings and withdrawal symptoms, and delays ad libitum smoking Type de document : texte imprimé Auteurs : Adrian Taylor, Auteur ; Magdalena Katomeri, Auteur Editeur : Oxford University Press Année de publication : 2007 Collection : Nicotine and Tobacco Research num. 9 (11) Importance : p.1183-1190 Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette
[TABAC] sevrage tabagique
[TABAC] tabagisme:aspect psychologique:comportement:addiction
[TABAC] tabagisme:risque:facteur associé:sportIndex. décimale : TA 6.7 Facteurs influents (grossesse, adolescence…) Résumé : La marche réduit le besoin de fumer des mégots de cigarettes et les symptômes de sevrage, et retarde le tabagisme à répétition Permalink : http://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2865 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002122 TA 6.7 TAY W Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !